12-15 OCTOBER 2020

Preliminary Program
Day 1 | Monday, 12 OCTOBER 2020

10:00 - 10:15 AM EDT  Welcome and Overview

10:15 - 11:00  Session 1: Blue Track | Geroscience – Major Recent Milestones
Moderator:
Matt Kaeberlein, PhD, Director of the Healthy Aging and Longevity Research Institute, University of Washington, USA
Brian Kennedy, PhD, Director of the Centre for Healthy Ageing at the National University Health System, Singapore
Gordon Lithgow, PhD, Professor and Vice President of Academic Affairs at the Buck Institute

11:00 - 11:45  Session 2: Red Track | Metabesity Diseases – Cancer
Moderator: Fred Hausheer, MD, PhD, FACP, Global Chief Medical Officer & Senior Vice President WuXi AppTec
Guido Kroemer, Director of the Metabolomics and Cell Biology Platforms of the Gustave Roussy Comprehensive Cancer Center
Brian Leyland-Jones, MB, BS, PhD, FRACP, FRCPC, Chief Medical Officer and Scientific Advisory Board Member for NFCR, USA
Jennifer Ligibel, MD, Director, Leonard P. Zakim Center for Integrative Therapies and Healthy Living, Dana-Farber Cancer Institute, USA

11:45 - 12:30 PM  Session 3: Red Track | Metabesity Diseases – Diabetes
Moderator: Jay Skyler, MD, MACP, Professor of Medicine, Pediatrics and Psychology at the University of Miami, USA
William Cefalu, MD, Director of the Division of Diabetes, Endocrinology & Metabolic Diseases, NIDDK/NIH, USA
Ralph DeFronzo, MD, Professor of Medicine, University of Texas Health Science Center, San Antonio, USA
Alyssa Hasty, PhD, Cornelius Vanderbilt Professor in the Department of Molecular Physiology & Biophysics at Vanderbilt University

12:30 - 12:35  Break
Day 1 | Monday, 12 OCTOBER 2020

12:35 - 13:20 PM EDT

Session 4: Yellow Track | Clinical Translation – Is Aging a Disease?
Nir Barzilai, MD, Director of Institute for Aging Research, Albert Einstein College of Medicine, USA
Stuart Caliimport, PhD, MSc, DIC, MA, MPhil, Honorary Fellow of the University of Liverpool Department of Musculoskeletal Biology II, Collaboration for the Advancement of Sustainable Medical Innovation Fellow at University College London
Luigi Ferrucci, MD, PhD, the Chief of the Longitudinal Studies Section at NIA and the Director of the Baltimore Longitudinal Study on Aging

13:20 - 14:05

Session 5: Yellow Track | Clinical Translation – Registrable Indications
Moderator: Alexander Fleming, MD, Founder and Executive Chairman of Kinexum & Chief Medical Officer of Tolerion, USA
James Peyer, PhD, Founder and CEO of Cambrian BioPharma
Joan Mannick, MD, Co-Founder and Chief Medical Officer of resTORbio, USA

14:05 - 14:50

Session 6: Purple Track | Living – Social, Psychological, and Environmental Drivers of Metabesity
Moderator: Lucy Rose, Founder and President of The Cost of Loneliness Project; Former Director, Division of Drug Advertising and Marketing, CDER, FDA
Dan Belsky, PhD, Assistant Professor in the Department of Epidemiology & Butler Aging Center at Columbia University Mailman School of Public Health
Amy Jeffs, Vice President of Status Solutions, Communications, Environmental, and Safety Awareness

14:50 - 15:35

Session 7: Brown Track | Business – Large Companies
Moderator: Joe Cook, Jr., Executive Chairman and President of NuSirt Biopharma; Former Chairman and CEO of Amylin, USA
Stephen Gough, MD, FRCP, Global Chief Medical Officer at Novo Nordisk
Antonio Tataranni, MD, Deputy Chief Scientific Officer and Senior Vice President of Life Sciences for PepsiCo R&D, USA

15:35 - 15:40

Break
Day 1 | Monday, 12 OCTOBER 2020

15:40 - 16:20 PM EDT

Session 8: Green Track | Policy – *Project Healthspan, Federal Legislation*
Adriane Berg, Executive Director of The Kitalys Institute
Alexander Fleming, MD, Founder and Executive Chairman of Kinexum & Chief Medical Officer of Tolerion, USA
David Fox, Partner at Hogan Lovells US LLP
Thomas Seoh, CEO, Kinexum

16:20 - 17:00

Session 9: Green Track | Policy – *The Longevity Dividend*
Dana Goldman, PhD, Interim Dean at the USC Sol Price School of Public Policy
Jay Olshansky, PhD, Professor at University of Illinois at Chicago’s School of Public Health

17:00 - 18:00

Session 10: Looking Ahead to Day 2 and Virtual Cocktail Hour
Day 2 | Tuesday, 13 OCTOBER 2020

10:00 - 10:05 AM EDT
Announcements

10:05 - 11:00
Session 11: Blue Track | Geroscience – Ready for Translation
Aubrey de Grey, PhD, Chief Science Officer of the SENS Research Foundation
Vadim Gladyshev, PhD, Professor of Medicine and Director, Center for Redox Medicine, Brigham and Women’s Hospital, Harvard Medical School, USA
Vittorio Sebastiano, PhD, Co-Founder of Turn Biotechnologies and Assistant Professor at Stanford University, USA

11:00 - 11:25
Keynote Speech: Victor Dzau, MD, President of the National Academy of Medicine

11:25 - 11:40
Q&A / Public Square

11:40 - 12:05 PM
Keynote Speech: Ken Dychtwald, PhD, CEO of Age Wave, USA

12:05 - 12:20
Q&A / Public Square

12:20 - 12:25
Break

12:25 - 13:10
Session 12: Yellow Track | Clinical Translation – Biological Clocks and Other Biomarkers of Aging for Product Development and Regulatory Approval
Moderator: Thomas Seoh, CEO of Kinexum
Steve Horvath, PhD, ScD, Professor, Human Genetics and Biostatistics at UCLA Brain Research Institute
Morgan Levine, PhD, Assistant Professor of Pathology and Epidemiology at Yale School of Medicine
Polina Mamoshina, PhD, Chief Scientist at Deep Longevity, Ltd. subsidiary of InSilico Medicine

13:10 - 13:55
Session 13: Yellow Track | Clinical Translation – The Clinical Trialist View
Moderator: Faiez Zannad, PhD, Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the Department of Cardiovascular Disease of the Academic Hospital in Nancy
[Speakers to be announced]
Day 2 | Tuesday, 13 OCTOBER 2020

13:55 - 14:55 PM EDT  
Session 14: Purple Track | Living – Why is Exercise Geroprotective? Molecular and Evolutionary Perspectives  
Moderator: Judy Foreman, Health Columnist and Author of Exercise is Medicine  
Daniel Lieberman, PhD, Edwin M Lerner II Professor of Biological Sciences, Department of Human Evolutionary Biology at Harvard University  
Thomas Rando, MD, PhD, Professor of Neurology at Stanford University

14:55 - 15:00  
Break

15:00 - 15:45  
Session 15: Red Track | Metabesity Diseases – Cardiovascular  
Dale Abel, MD, PhD, Chair of the Department of Internal Medicine and Director of the Fraternal Order of Eagles Diabetes Research Center at the Carver College of Medicine of the University of Iowa  
Pam R. Taub, MD, FACC, Cardiologist, Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center  
[Other speakers to be announced]

15:45 - 16:30  
Session 16: Red Track | Metabesity Diseases – Neurodegenerative Diseases  
Moderator: Lawrence Steinman, MD, Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford  
[Speakers to be announced]

16:30 - 17:15  
Session 17: Brown Track | Business – Emerging Companies  
Moderator: Ed Salzman, Executive Chairman at Cello Health BioConsulting  
Ben Gibson, CEO of Pano Therapeutics  
Ashish Nimgaonkar, MD, Chief Executive Officer of Glyscend  
Alex Zhavoronkov, PhD, Chief Longevity Officer at Deep Longevity and CEO of InSilico Medicine

17:15 - 18:15  
Virtual Cocktail Hour
Day 3 | Wednesday, 14 OCTOBER 2020

10:00 - 10:05 AM EDT  Announcements

10:05 - 11:00  Session 18: Blue Track | **Geroscience – Mitochondria and Health**
**Moderator:** Doug Wallace, PhD, Director of Center for Mitochondrial and Epigenomic Medicine at Children’s Hospital of Philadelphia, USA
**Francesca Fieni, PhD,** Founder and CSO, Pano Therapeutics, Inc.
**Hazel Szeto, MD, PhD,** Director of Research, Social Profit Network
**Michael Zemel, PhD,** Founder and Chief Scientific Officer of NuSirt Biopharma, USA

11:00 - 11:25  Keynote Speech: Lord Geoffrey Filkin, CBE, Chair of APPG for Longevity, Strategic Advisory Group, UK

11:25 - 11:40  Q&A / Public Square

11:40 - 12:25 PM  Session 19: Green Track | **Policy – Global Lessons**
**Moderator:** Eric Kihlstrom, Secretariat of UK All-Party Parliamentary Group for Longevity and Strategic Director of Aging Analytics Agency
**Jamie Metzl,** Author of Hacking Darwin
**Richard Siow, PhD,** Director of Ageing Research at King’s College London, UK
**Tina Woods,** Founder and Chief Executive Officer of Collider Health, UK

12:25 - 13:05  Session 20: Red Track | **Metabesity Diseases – Immunity Decline and Coronavirus**
**Nir Barzilai, MD,** Director of Institute for Aging Research, Albert Einstein College of Medicine, USA
**Joan Mannick, MD,** Co-Founder and Chief Medical Officer of resTORbio, USA
**Lawrence Steinman, MD,** Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford

13:05 - 13:10  Break
Day 3 | Wednesday, 14 OCTOBER 2020

13:10 - 13:55 PM EDT

**Session 21: Red Track | Metabesity Diseases – Diabesity**

*Moderator: Jay Skyler, MD, MACP*, Professor of Medicine, Pediatrics and Psychology at the University of Miami, USA

*Brian Harvey, MD, PhD*, Global Liver Institute, Former Director, Division of Gastroenterology Products, Center for Drug Evaluation and Research

*Philip Home*, Professor of Diabetes Medicine at University of Newcastle, UK

*Steven Smith, MD*, Chief Scientific Officer of Advent Health Orlando Research Services

13:55 - 14:40

**Session 22: Purple Track | Living – Nutrition**

*Michael Lustgarten, PhD*, Scientist II at USDA Jean Mayer Human Nutrition Research Center on Aging

*Susan Mayne, PhD*, Director of FDA Center for Food Safety and Applied Nutrition, USA

*Kris Verburgh, MD*, Researcher at the Free University Brussels, Belgium, and Venture Partner of Longevity Vision Fund

14:40 - 14:45

**Break**

14:45 - 15:30

**Session 23: Brown Track | Business – Capital Markets**

*Moderator: Dennis Purcell*, Founder and Senior Advisor, Aisling Capital, USA

*Kate Batz*, Managing Partner of Longevity Capital, USA

*Laura Deming*, Founder and Managing Partner of The Longevity Fund, USA

*James Peyer, PhD*, Founder and CEO of Cambrian BioPharma

15:30 - 15:50

**Closing Keynote Speaker and View to the Future**

15:50 - 16:00

**Conference Wrap-Up**

16:00 - 17:00

**Gala**
Day 4 | Thursday, 15 OCTOBER 2020

11:00 - 11:15 AM EDT

**Welcome:** Phil Newman, Editor-In-Chief at Longevity Technology

**Emerging Company Showcase**
[Partial alphabetical list; order of presentations to be supplied]

**AgelessRx | Anar Isman, Co-Founder and CEO**
Make prescription products with longevity benefits accessible to everyone as new therapies for metabesity are shown to be effective and save. Currently offer metformin and prescription NAD product, and are working on launching a clinical trial of rapamycin for longevity.

**ALMS Therapeutics | Vincent Marion, CEO**
An adipocyte curing company using an ultra-rare genetic disorder, the ALMS syndrome, to develop a biologic that targets the adipocyte, which is able to treat common diseases, such as type 2 diabetes and its associated comorbidities.

**Amazentis SA | Anurag Singh, MD, PhD, CMO**
An innovative life sciences company employing leading research and clinical science to develop products targeting mitochondrial health for advanced nutrition, such as Urolithin A (Mitopure™), which has been shown to improve mitochondrial function by stimulating mitophagy.

**CohBar | Steve Engle, CEO**
A clinical stage biotechnology company focused on mitochondria-based therapeutics that originate from a novel group of naturally occurring peptide sequences within the mitochondrial genome. This emerging class of drugs for the treatment of chronic and age-related diseases includes the company’s lead compound, CB4211, which is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity.

**Deep Longevity | Alex Zhavoronkov, PhD, Chief Longevity Officer**
Develop explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels, as well as develop systems for the emerging field of longevity medicine, which allows physicians to make better decisions on the interventions that may slow down or reverse the aging processes.
Day 4 | Thursday, 15 OCTOBER 2020

Emerging Company Showcase Continued...

**Genflow Biosciences | Eric Leire, CEO**
Private biotech company dedicated to the development of a safe gene therapy to halt, slow, or reverse the aging process. The company uses its proprietary technology (patent pending) for an episomal, transient delivery of extra copies of SIRT6 gene through minicircle plasmids, to extend lifespan and increase health span of dogs and humans.

**Gila Therapeutics, Inc. | Thomas Vasicek, PhD, Co-Founder and CEO**
Privately held clinical-stage pharmaceutical company that develops and commercializes innovative, effective, and safe therapies for metabolic diseases, using novel routes of administration.

**Glyscend | Ashish Nimgaonkar, MD, CEO**
A biopharmaceutical company developing novel orally-delivered compounds that work on targets inside the GI tract to treat a variety of metabolic disorders, including T2D.

**InSilico Medicine | Alex Zhavoronkov, PhD, CEO**
A biotechnological company using artificial intelligence and deep-learning techniques in drug development and discovery.

**Medality Medical, LLC | Larry Hirsch, MD, CMA**
Engaged in a Sponsor-initiated, First-in-Human Mesenteric Visceral Lipectomy (MVL) Clinical Trial evaluating the safety and efficacy of their proprietary HydraSolve T2D system to extract mesenteric fat during the investigational MVL procedure, in an effort to reduce insulin resistance and reverse type 2 diabetes.

**Nuritas | Nora Khaldi, PhD, Founder and CSO**
Combines AI and peptidomics to discover bioactive peptides with extraordinary health benefits.

**Pano Therapeutics | Ben Gibson, CEO**
Developing synthetic and natural compound formulations targeting the mitochondrial proton motive force to address complex diseases of aging.
Emerging Company Showcase Continued...

**Stealth Biotherapeutics Inc. | Reenie McCarthy, CEO**
Developing mitochondrial targeted therapeutics to address the mitochondrial function associated with many rare genetic diseases, neurodegenerative diseases, and common diseases of aging. Their lead compound has been shown to improve mitochondrial structure and function across multiple disease models — improving ATP production, decreasing oxidative stress and reducing inflammation, fibrosis and cell death.

**THOR | James Carroll, CEO**
Developed photobiomodulation (PBM Therapy) in which light (within certain parameters) regenerates tissue, reduces inflammation, and reduces pain by increasing cellular energy and reducing oxidative stress.

**Unify Pharmaceuticals | Laura Dugan, MD, CEO**
A biotech company developing drugs to target neurodegenerative diseases such as Parkinson’s Disease, Myocardial Infarction, Macular Degeneration, Alzheimer’s, and Strokes. Their UP-1007 is the first-in-class water-soluble fullerene shown to successfully target the underlying causes of Parkinson’s and other diseases involving oxidative damage.